军事知识服务平台
EB病毒相关临床疾病的研究新进展
Emerging research progress on Epstein-Barr virus-related clinical diseases
摘要 EB病毒(EBV)感染全球95%以上人口,与多种肿瘤及非肿瘤疾病密切相关。近年来,在EBV相关疾病的诊疗领域取得多项重要进展。诊断方面,新型血清标志物p85总抗体对鼻咽癌高发区筛查的敏感度和特异度显著优于传统抗体联合检测,已被纳入临床专家共识。治疗方面,基于抗体的B细胞耗竭疗法(如利妥昔单抗)可有效预防移植后淋巴增殖性疾病,并对进行性多发性硬化症显示良好疗效;免疫检查点抑制剂在EBV相关胃癌及霍奇金淋巴瘤中疗效突出;同种异体造血干细胞移植已将慢性活动性EBV病长期生存率提升至55%~65%,并使成人EBV相关噬血细胞性淋巴组织细胞增多症5年总生存率提升到48.7%。预防方面,针对gp350、gH/gL的预防性疫苗及靶向LMP2的治疗性mRNA疫苗已进入临床试验阶段。新近这些进展为EBV相关疾病的精准诊疗和基础研究提供了新方向。
Abstract:
Epstein-Barr virus (EBV) infects over 95% of the global population and is closely associated with various tumor and non-tumor diseases. In recent years, significant progress has been made in the diagnosis and treatment of EBV related diseases. In terms of diagnosis, the sensitivity and specificity of the new serum marker p85 total antibody in screening high-risk areas for nasopharyngeal carcinoma are significantly better than traditional antibody combination testing, and have been included in the consensus of clinical experts. In terms of treatment, antibody based B-cell depletion therapy (such as rituximab) can effectively prevent post-transplant lymphoproliferative diseases and demonstrate good efficacy in treating progressive multiple sclerosis; Immune checkpoint inhibitors have shown outstanding efficacy in EBV associated gastric cancer and Hodgkin lymphoma; Allogeneic hematopoietic stem cell transplantation has increased the long-term survival rate of chronic active EB virus disease to 55% to 65%, and has resulted in a 5-year overall survival rate of 48.7% for adult EBV related hemophagocytic lymphohistiocytosis. In terms of prevention, preventive vaccines targeting gp350 and gH/gL, as well as therapeutic mRNA vaccines targeting LMP2, have entered the clinical trial stage. The above progress provides new directions for precise diagnosis,treatment, and basic research of EBV related diseases.